| Oct 30 |
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
|
| Oct 25 |
Unveiling 12 Analyst Insights On Halozyme Therapeutics
|
| Oct 24 |
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
|
| Oct 23 |
Halozyme to Report Third Quarter 2024 Financial and Operating Results
|
| Oct 22 |
Halozyme Therapeutics: Behind The Pullback
|
| Oct 14 |
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
|
| Oct 8 |
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
| Oct 7 |
Halozyme Therapeutics shares fall as Wells Fargo cuts rating to equal weight
|
| Oct 7 |
Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again
|
| Oct 3 |
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
|
